Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Influenza vaccine, inactivated, subunit, trivalent** is a **seasonal vaccine** containing purified hemagglutinin (HA) subunits from three influenza virus strains (two A subtypes, typically H1N1 and H3N2, and one B lineage, most recently B/Victoria lineage). It is **manufactured by inactivating virus grown in eggs or cell culture, splitting the viral particles, and further purifying subunits, chiefly the HA protein**. This vaccine induces immunity primarily by stimulating antibody production against the influenza virus HA and, to a lesser extent, NA proteins, thereby preventing infection or reducing disease severity. It is administered annually, with protection tailored to circulating viral strains under WHO and FDA recommendations. Indicated for all eligible individuals 6 months and older, especially in populations at higher risk of influenza complications[1][3][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on influenza vaccine, inactivated, subunit, trivalent.